aluates Reports

$ 0.0

Automative

Oncology Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: September 2024

Report Code: QYRE-Auto-37P6846

Global Oncology Biosimilars Market Insights and Forecast to 2028

BUY CHAPTERS

Oncology Biosimilars - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-37P6846

Report

September 2024

Pages:104

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Celltrion

Biocon Ltd.

Dr. Reddy’s Laboratories

STADA Arzneimittel AG

Intas Pharmaceuticals

Pfizer Inc

Sandoz International

Teva Pharmaceutical Industries Ltd

Apotex

BIOCAD

Oncology Biosimilars - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Oncology Biosimilars - Market

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

The global market for Oncology Biosimilars was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oncology Biosimilars, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Oncology Biosimilars by region & country, by Type, and by Application.

The Oncology Biosimilars market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Biosimilars.

Market Segmentation

Scope of Oncology Biosimilars - Market Report

Report Metric	Details
Report Name	Oncology Biosimilars - Market
CAGR	5%
Segment by Type:	Monoclonal Antibody Hematopoietic Agents G-CSF Others
Segment by Application	Retail Pharmacies Hospital Pharmacy Online Pharmacy
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Oncology Biosimilars manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Oncology Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Oncology Biosimilars in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Oncology Biosimilars - Market report?

Ans: The main players in the Oncology Biosimilars - Market are Celltrion, Biocon, Dr. Reddy’s Laboratories, STADA Arzneimittel AG, Intas Pharmaceuticals, Pfizer, Sandoz International, Teva Pharmaceutical Industries Ltd, Apotex, BIOCAD

What are the Application segmentation covered in the Oncology Biosimilars - Market report?

Ans: The Applications covered in the Oncology Biosimilars - Market report are Retail Pharmacies, Hospital Pharmacy, Online Pharmacy

What are the Type segmentation covered in the Oncology Biosimilars - Market report?

Ans: The Types covered in the Oncology Biosimilars - Market report are Monoclonal Antibody, Hematopoietic Agents, G-CSF, Others

Recommended Reports

Oncology Treatment Drugs

Biosimilars & Biologic Therapy

Cancer Diagnostics & Cell Therapy

1 Market Overview

1.1 Oncology Biosimilars Product Introduction

1.2 Global Oncology Biosimilars Market Size Forecast

1.3 Oncology Biosimilars Market Trends & Drivers

1.3.1 Oncology Biosimilars Industry Trends

1.3.2 Oncology Biosimilars Market Drivers & Opportunity

1.3.3 Oncology Biosimilars Market Challenges

1.3.4 Oncology Biosimilars Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Oncology Biosimilars Players Revenue Ranking (2023)

2.2 Global Oncology Biosimilars Revenue by Company (2019-2024)

2.3 Key Companies Oncology Biosimilars Manufacturing Base Distribution and Headquarters

2.4 Key Companies Oncology Biosimilars Product Offered

2.5 Key Companies Time to Begin Mass Production of Oncology Biosimilars

2.6 Oncology Biosimilars Market Competitive Analysis

2.6.1 Oncology Biosimilars Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Oncology Biosimilars Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Monoclonal Antibody

3.1.2 Hematopoietic Agents

3.1.3 G-CSF

3.1.4 Others

3.2 Global Oncology Biosimilars Sales Value by Type

3.2.1 Global Oncology Biosimilars Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Oncology Biosimilars Sales Value, by Type (2019-2030)

3.2.3 Global Oncology Biosimilars Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Retail Pharmacies

4.1.2 Hospital Pharmacy

4.1.3 Online Pharmacy

4.2 Global Oncology Biosimilars Sales Value by Application

4.2.1 Global Oncology Biosimilars Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Oncology Biosimilars Sales Value, by Application (2019-2030)

4.2.3 Global Oncology Biosimilars Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Oncology Biosimilars Sales Value by Region

5.1.1 Global Oncology Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Oncology Biosimilars Sales Value by Region (2019-2024)

5.1.3 Global Oncology Biosimilars Sales Value by Region (2025-2030)

5.1.4 Global Oncology Biosimilars Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Oncology Biosimilars Sales Value, 2019-2030

5.2.2 North America Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Oncology Biosimilars Sales Value, 2019-2030

5.3.2 Europe Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Oncology Biosimilars Sales Value, 2019-2030

5.4.2 Asia Pacific Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Oncology Biosimilars Sales Value, 2019-2030

5.5.2 South America Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Oncology Biosimilars Sales Value, 2019-2030

5.6.2 Middle East & Africa Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Oncology Biosimilars Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Oncology Biosimilars Sales Value

6.3 United States

6.3.1 United States Oncology Biosimilars Sales Value, 2019-2030

6.3.2 United States Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Oncology Biosimilars Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Oncology Biosimilars Sales Value, 2019-2030

6.4.2 Europe Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Oncology Biosimilars Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Oncology Biosimilars Sales Value, 2019-2030

6.5.2 China Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.5.3 China Oncology Biosimilars Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Oncology Biosimilars Sales Value, 2019-2030

6.6.2 Japan Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Oncology Biosimilars Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Oncology Biosimilars Sales Value, 2019-2030

6.7.2 South Korea Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Oncology Biosimilars Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Oncology Biosimilars Sales Value, 2019-2030

6.8.2 Southeast Asia Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Oncology Biosimilars Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Oncology Biosimilars Sales Value, 2019-2030

6.9.2 India Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

6.9.3 India Oncology Biosimilars Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Celltrion

7.1.1 Celltrion Profile

7.1.2 Celltrion Main Business

7.1.3 Celltrion Oncology Biosimilars Products, Services and Solutions

7.1.4 Celltrion Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.1.5 Celltrion Recent Developments

7.2 Biocon

7.2.1 Biocon Profile

7.2.2 Biocon Main Business

7.2.3 Biocon Oncology Biosimilars Products, Services and Solutions

7.2.4 Biocon Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.2.5 Biocon Recent Developments

7.3 Dr. Reddy’s Laboratories

7.3.1 Dr. Reddy’s Laboratories Profile

7.3.2 Dr. Reddy’s Laboratories Main Business

7.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Products, Services and Solutions

7.3.4 Dr. Reddy’s Laboratories Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.3.5 STADA Arzneimittel AG Recent Developments

7.4 STADA Arzneimittel AG

7.4.1 STADA Arzneimittel AG Profile

7.4.2 STADA Arzneimittel AG Main Business

7.4.3 STADA Arzneimittel AG Oncology Biosimilars Products, Services and Solutions

7.4.4 STADA Arzneimittel AG Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.4.5 STADA Arzneimittel AG Recent Developments

7.5 Intas Pharmaceuticals

7.5.1 Intas Pharmaceuticals Profile

7.5.2 Intas Pharmaceuticals Main Business

7.5.3 Intas Pharmaceuticals Oncology Biosimilars Products, Services and Solutions

7.5.4 Intas Pharmaceuticals Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.5.5 Intas Pharmaceuticals Recent Developments

7.6 Pfizer

7.6.1 Pfizer Profile

7.6.2 Pfizer Main Business

7.6.3 Pfizer Oncology Biosimilars Products, Services and Solutions

7.6.4 Pfizer Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.6.5 Pfizer Recent Developments

7.7 Sandoz International

7.7.1 Sandoz International Profile

7.7.2 Sandoz International Main Business

7.7.3 Sandoz International Oncology Biosimilars Products, Services and Solutions

7.7.4 Sandoz International Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.7.5 Sandoz International Recent Developments

7.8 Teva Pharmaceutical Industries Ltd

7.8.1 Teva Pharmaceutical Industries Ltd Profile

7.8.2 Teva Pharmaceutical Industries Ltd Main Business

7.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Products, Services and Solutions

7.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.8.5 Teva Pharmaceutical Industries Ltd Recent Developments

7.9 Apotex

7.9.1 Apotex Profile

7.9.2 Apotex Main Business

7.9.3 Apotex Oncology Biosimilars Products, Services and Solutions

7.9.4 Apotex Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.9.5 Apotex Recent Developments

7.10 BIOCAD

7.10.1 BIOCAD Profile

7.10.2 BIOCAD Main Business

7.10.3 BIOCAD Oncology Biosimilars Products, Services and Solutions

7.10.4 BIOCAD Oncology Biosimilars Revenue (US$ Million) & (2019-2024)

7.10.5 BIOCAD Recent Developments

8 Industry Chain Analysis

8.1 Oncology Biosimilars Industrial Chain

8.2 Oncology Biosimilars Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Oncology Biosimilars Sales Model

8.5.2 Sales Channel

8.5.3 Oncology Biosimilars Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Celltrion

Biocon Ltd.

Dr. Reddy’s Laboratories

STADA Arzneimittel AG

Intas Pharmaceuticals

Pfizer Inc

Sandoz International

Teva Pharmaceutical Industries Ltd

Apotex

BIOCAD

List of Tables

Table 1. Oncology Biosimilars Market Trends

Table 2. Oncology Biosimilars Market Drivers & Opportunity

Table 3. Oncology Biosimilars Market Challenges

Table 4. Oncology Biosimilars Market Restraints

Table 5. Global Oncology Biosimilars Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Oncology Biosimilars Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Oncology Biosimilars Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Oncology Biosimilars Product Type

Table 9. Key Companies Time to Begin Mass Production of Oncology Biosimilars

Table 10. Global Oncology Biosimilars Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Biosimilars as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Oncology Biosimilars Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Oncology Biosimilars Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Oncology Biosimilars Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Oncology Biosimilars Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Oncology Biosimilars Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Oncology Biosimilars Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Oncology Biosimilars Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Oncology Biosimilars Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Oncology Biosimilars Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Oncology Biosimilars Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Oncology Biosimilars Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Oncology Biosimilars Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Oncology Biosimilars Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Oncology Biosimilars Sales Value by Region (2019-2024) & (%)

Table 27. Global Oncology Biosimilars Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Oncology Biosimilars Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Oncology Biosimilars Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Oncology Biosimilars Sales Value, (2025-2030) & (US$ Million)

Table 31. Celltrion Basic Information List

Table 32. Celltrion Description and Business Overview

Table 33. Celltrion Oncology Biosimilars Products, Services and Solutions

Table 34. Revenue (US$ Million) in Oncology Biosimilars Business of Celltrion (2019-2024)

Table 35. Celltrion Recent Developments

Table 36. Biocon Basic Information List

Table 37. Biocon Description and Business Overview

Table 38. Biocon Oncology Biosimilars Products, Services and Solutions

Table 39. Revenue (US$ Million) in Oncology Biosimilars Business of Biocon (2019-2024)

Table 40. Biocon Recent Developments

Table 41. Dr. Reddy’s Laboratories Basic Information List

Table 42. Dr. Reddy’s Laboratories Description and Business Overview

Table 43. Dr. Reddy’s Laboratories Oncology Biosimilars Products, Services and Solutions

Table 44. Revenue (US$ Million) in Oncology Biosimilars Business of Dr. Reddy’s Laboratories (2019-2024)

Table 45. Dr. Reddy’s Laboratories Recent Developments

Table 46. STADA Arzneimittel AG Basic Information List

Table 47. STADA Arzneimittel AG Description and Business Overview

Table 48. STADA Arzneimittel AG Oncology Biosimilars Products, Services and Solutions

Table 49. Revenue (US$ Million) in Oncology Biosimilars Business of STADA Arzneimittel AG (2019-2024)

Table 50. STADA Arzneimittel AG Recent Developments

Table 51. Intas Pharmaceuticals Basic Information List

Table 52. Intas Pharmaceuticals Description and Business Overview

Table 53. Intas Pharmaceuticals Oncology Biosimilars Products, Services and Solutions

Table 54. Revenue (US$ Million) in Oncology Biosimilars Business of Intas Pharmaceuticals (2019-2024)

Table 55. Intas Pharmaceuticals Recent Developments

Table 56. Pfizer Basic Information List

Table 57. Pfizer Description and Business Overview

Table 58. Pfizer Oncology Biosimilars Products, Services and Solutions

Table 59. Revenue (US$ Million) in Oncology Biosimilars Business of Pfizer (2019-2024)

Table 60. Pfizer Recent Developments

Table 61. Sandoz International Basic Information List

Table 62. Sandoz International Description and Business Overview

Table 63. Sandoz International Oncology Biosimilars Products, Services and Solutions

Table 64. Revenue (US$ Million) in Oncology Biosimilars Business of Sandoz International (2019-2024)

Table 65. Sandoz International Recent Developments

Table 66. Teva Pharmaceutical Industries Ltd Basic Information List

Table 67. Teva Pharmaceutical Industries Ltd Description and Business Overview

Table 68. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Products, Services and Solutions

Table 69. Revenue (US$ Million) in Oncology Biosimilars Business of Teva Pharmaceutical Industries Ltd (2019-2024)

Table 70. Teva Pharmaceutical Industries Ltd Recent Developments

Table 71. Apotex Basic Information List

Table 72. Apotex Description and Business Overview

Table 73. Apotex Oncology Biosimilars Products, Services and Solutions

Table 74. Revenue (US$ Million) in Oncology Biosimilars Business of Apotex (2019-2024)

Table 75. Apotex Recent Developments

Table 76. BIOCAD Basic Information List

Table 77. BIOCAD Description and Business Overview

Table 78. BIOCAD Oncology Biosimilars Products, Services and Solutions

Table 79. Revenue (US$ Million) in Oncology Biosimilars Business of BIOCAD (2019-2024)

Table 80. BIOCAD Recent Developments

Table 81. Key Raw Materials Lists

Table 82. Raw Materials Key Suppliers Lists

Table 83. Oncology Biosimilars Downstream Customers

Table 84. Oncology Biosimilars Distributors List

Table 85. Research Programs/Design for This Report

Table 86. Key Data Information from Secondary Sources

Table 87. Key Data Information from Primary Sources

Table 88. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Oncology Biosimilars Product Picture

Figure 2. Global Oncology Biosimilars Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Oncology Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 4. Oncology Biosimilars Report Years Considered

Figure 5. Global Oncology Biosimilars Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Oncology Biosimilars Revenue in 2023

Figure 7. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Monoclonal Antibody Picture

Figure 9. Hematopoietic Agents Picture

Figure 10. G-CSF Picture

Figure 11. Others Picture

Figure 12. Global Oncology Biosimilars Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 13. Global Oncology Biosimilars Sales Value Market Share by Type, 2023 & 2030

Figure 14. Product Picture of Retail Pharmacies

Figure 15. Product Picture of Hospital Pharmacy

Figure 16. Product Picture of Online Pharmacy

Figure 17. Global Oncology Biosimilars Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 18. Global Oncology Biosimilars Sales Value Market Share by Application, 2023 & 2030

Figure 19. North America Oncology Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 20. North America Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 21. Europe Oncology Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 22. Europe Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 23. Asia Pacific Oncology Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 24. Asia Pacific Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 25. South America Oncology Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 26. South America Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 27. Middle East & Africa Oncology Biosimilars Sales Value (2019-2030) & (US$ Million)

Figure 28. Middle East & Africa Oncology Biosimilars Sales Value by Country (%), 2023 VS 2030

Figure 29. Key Countries/Regions Oncology Biosimilars Sales Value (%), (2019-2030)

Figure 30. United States Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 31. United States Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 32. United States Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 33. Europe Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 34. Europe Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 35. Europe Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 36. China Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 37. China Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 38. China Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 39. Japan Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 40. Japan Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 41. Japan Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 42. South Korea Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 43. South Korea Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 44. South Korea Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 45. Southeast Asia Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 46. Southeast Asia Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 47. Southeast Asia Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 48. India Oncology Biosimilars Sales Value, (2019-2030) & (US$ Million)

Figure 49. India Oncology Biosimilars Sales Value by Type (%), 2023 VS 2030

Figure 50. India Oncology Biosimilars Sales Value by Application (%), 2023 VS 2030

Figure 51. Oncology Biosimilars Industrial Chain

Figure 52. Oncology Biosimilars Manufacturing Cost Structure

Figure 53. Channels of Distribution (Direct Sales, and Distribution)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Biosimilar Drug Market

Bevacizumab Biosimilar Market

Infliximab and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Filgrastim and Biosimilars Market Research Report 2024

Generic and Biosimilar Pharmaceuticals Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cetuximab Biosimilar Market Research Report 2025

Recombinant Glycosylated Proteins Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Herceptin Biosimilar Market Insights Forecast to 2030

Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Generic Oncology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Adalimumab Infliximab And Etanercept Biosimilars Market Research Report 2024

Glycosylated Biosimilars Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-14Y6812

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-34O3983

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-9V17601

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22C17047

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions